Objectives: HIV/hepatitis B virus (HBV) coinfection is common in Ghana, where first-line antiretroviral therapy (ART) comprises lamivudine with zidovudine or stavudine and nevirapine or efavirenz. Little is known about ART outcomes in the context of coinfection. This study evaluated outcomes of ART among HIV/HBV-coinfected Ghanaians, focusing on locally available parameters.
Introduction
Between 2% and 20% of HIV-positive individuals in sub-Saharan Africa are also infected with hepatitis B virus (HBV), 1, 2 with West Africa showing the highest rates of coinfection. HBV transmission in sub-Saharan Africa usually occurs in early childhood, many years before HIV is acquired, 1 and most patients presenting with HIV have not received childhood HBV vaccination. Despite high seroprevalence rates, HBV screening is often not part of routine HIV care, hampered by cost and limited laboratory infrastructure. We previously reported that the prevalence of HBV coinfection was 16.7% among HIV-positive patients in Kumasi, Ghana, with predominantly HBV genotype E. 2 HIV accelerates the progression of liver disease in HIV/HBV coinfection 3 -6 and coinfected patients show an increased risk of hepatotoxicity of antiretroviral drugs. 7 It is less clear whether HBV influences the progression of HIV infection, or response to antiretroviral therapy (ART), particularly in Africa, where few studies have been reported. 5, 6 Most ART programmes in Africa include lamivudine in first-line regimens. While lamivudine is also active against HBV, drug resistance develops over time in most coinfected patients receiving lamivudine as the sole anti-HBV agent. 8 As ART roll-out progresses in Africa, there will be more Africans developing long-term complications of poorly controlled HBV infection, including cirrhosis and hepatocellular carcinoma, which may be preventable with optimal antiviral therapy.
The aim of this study was to characterize the impact of HBV coinfection on the outcomes of first-line ART in a cohort attending a single centre in Kumasi, Ghana, using measures that are routinely available locally. In a random subset of patients, HBV-DNA levels and bulk HBV polymerase sequences were obtained using stored samples.
Patients and methods
In 2007, stored sera from all adult patients attending the HIV clinic at Komfo Anokye Teaching Hospital in Kumasi, Ghana, underwent hepatitis B surface antigen (HBsAg) screening as described previously.
2 HBsAgpositive patients who started ART between 2004 and 2008, according to national and WHO guidelines, were evaluated retrospectively for available demographic, clinical and laboratory data. The endpoints for the study were change in body mass index (BMI), CD4 count and haemoglobin (Hb), alanine transaminase (ALT) and aspartate aminotransferase (AST) elevations, clinical events, default from follow-up, and changes in ART, all measured after 1 month and 6 monthly thereafter, until censoring at the end of 2009. Data from HBsAg-negative patients within a previously described cohort were used for comparison. 9 First-line therapy consisted of zidovudine (or stavudine if Hb ,8 g/dL), lamivudine and efavirenz (or nevirapine if female). HBsAg status was not known to the attending physician at the initiation of ART nor during the first 2 years on ART. The study was approved by the Committee on Human Research Publications and Ethics at Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana.
HBV-DNA levels were measured in a random subset of 91 HBsAgpositive patients who had sufficient serum/plasma stored at 2208C, using a quantitative real-time PCR assay with a lower limit of quantification of 14 IU/mL. Samples with detectable HBV-DNA underwent bulk sequencing of the polymerase gene reverse transcriptase domain (amino acids 1-344), as described previously. 2 Characteristics measured at the time of ART initiation were compared between HBsAg-positive and HBsAg-negative individuals using t-tests or Kruskal-Wallis tests for continuous variables and x 2 or Fisher's exact tests for categorical variables. Mixed-effects models were used to assess the relationship between HBV coinfection status and CD4 cell count and BMI changes over time. 10 Logistic regression analyses were used to explore factors associated with raised transaminase levels up to 1 year after starting ART. Statistical analyses were performed using STATA software.
Results
Among 323 patients identified with HBsAg seropositivity, 143 started ART and had sufficient data for analysis. A population of 228 HBsAg-negative patients served as the comparator group. At ART initiation, compared with HBsAg-negative patients, HBsAgpositive patients were slightly younger, were more likely to start stavudine rather than zidovudine, had higher CD4 cell counts (133 versus 119 cells/mm 3 ), showed higher Hb levels and were more likely to show transaminase elevations, albeit mostly low grade ( Table 1 ). The median (IQR) duration of follow-up was 18 months (6-30) and 36 months (12-36) for HBsAg-positive and HBsAg-negative patients, respectively. The number of new clinical events (10.5% and 13.2%, respectively), default from follow-up (30.8% and 36.4%, respectively) and discontinuation of ART (5.6% and 4.8%, respectively) at censoring were similar in the two populations. In a mixed-effects model, coinfected patients showed a 2.04 (95% CI 0.59-3.49) cells/mm 3 /month smaller CD4 count increase after adjustment for confounders (Table 2 ). Other factors independently associated with reduced CD4 cell count increases were higher baseline CD4 counts, lower baseline Hb and zidovudine (rather than stavudine) use (Table 2) . In a similar model, HBV coinfection did not influence changes in BMI. Factors associated with a larger increase in BMI, in both unadjusted and multivariable analyses, were female gender, lower baseline Hb and lower baseline BMI.
Raised transaminases were more common in HBsAg-positive patients, both at baseline and after starting ART; however, the frequency of transaminase elevations decreased in this population after starting ART. Transaminase elevations were predominantly of grade 1/2. There was only one patient who experienced a grade 4 transaminase elevation during the first 12 months of ART and this patient was HBsAg negative. Using logistic regression analysis, HBV coinfection was the only independent factor associated with raised transaminases (grade ≥1) during the first 12 months of ART. Within the HBsAg-positive population, none of the factors analysed was associated with raised transaminases, neither was use of nevirapine or stavudine (rather than efavirenz or zidovudine) at any timepoint analysed (data not shown).
Within the HBsAg-positive population, 35/143 (24.5%) patients (a random subset) had samples available for HBV-DNA testing prior to starting ART and, of these, 37.9% were hepatitis B e-antigen (HBeAg) positive. The median HBV-DNA was 4.1 log 10 IU/mL (IQR 2.7-6.4); 23/35 (65.7%) patients showed a HBV-DNA level .2000 IU/mL. A further 66/143 (46.2%) patients had a sample available for HBV-DNA testing during ART. After a median of 9 months (IQR 6-20) of ART, the median HBV-DNA declined to 3.3 log 10 IU/mL (IQR 2.6 -6.2), with 33/66 (50.0%) patients having HBV-DNA levels .2000 IU/ mL and only 2/66 (3.0%) patients showed an undetectable (,14 IU/mL) HBV-DNA. Bulk HBV polymerase sequences were obtained from 53/55 patients with detectable HBV-DNA. HBV drug resistance mutations reflective of lamivudine selective pressure (M204I; M204V with or without L80I, V173L and L180M) were identified in 12/53 (22.6%) patients.
Discussion
This study demonstrated that HBV coinfection was associated with increased (predominantly mild) transaminase elevations, but not more ART discontinuations or clinical events relative to HBsAg-negative patients. Interestingly, however, there was a small but significant negative impact of HBV coinfection on CD4 count recovery during ART, which persisted after adjustment for some potential confounders. This observation, if confirmed in larger studies, contrasts with findings in other studies in Africa; 5, 6 the reasons for this discrepancy remain to be elucidated. HBV-DNA levels were high in untreated HIV-positive patients and commonly above the threshold of 2000 IU/mL, implying a serious potential for progressive liver damage. As in most African countries, patients in Ghana receive first-line ART containing lamivudine as the sole agent with activity against HBV. Although only a proportion of coinfected patients had samples The following data were missing from the medical records: age, n¼3; BMI, n ¼17; Hb, n ¼27; CD4 cell count, n¼5; WHO stage, n¼4; and transaminase level, n ¼47. The HBsAg status was determined retrospectively 1 -2 years after starting therapy using stored serum samples. c ATCG grading of transaminase (ALT or AST) levels: 0, ,1.25 upper limit of normal (ULN); 1, 1.25-2.5× ULN; 2, 2.6-5× ULN; 3, 5.1-10× ULN; 4, .10× ULN. Mixed-effects models were used to assess the relationship between each factor of interest and CD4 cell count change (see Laird and Ware 10 ).
b
The duration of ART was incorporated into the multivariable model as interactions with each variable individually, in order to allow for fluctuating slopes. As a result, duration of ART was not included as a separate variable in this model.
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JAC available for testing, it was evident that patients still had high HBV-DNA levels after a median 9 months of ART. We also found evidence for emerging resistance, with nearly one-quarter of patients showing lamivudine-associated resistance mutations. Hence, the projections for the accumulation of resistance over longer follow-up, with the associated implications in terms of progressive liver disease, are alarming. Nearly half of all patients received nevirapine, yet HBV-coinfected patients receiving nevirapine were no more likely to develop raised transaminases or switch ART than those on efavirenz. These results provide reassurance that both nevirapine and efavirenz are safe options in HBV-coinfected patients, as are stavudine and zidovudine in the short term. Our study has a number of limitations. First, it was only possible to retrieve samples for molecular HBV studies in a subset of patients. Second, patients were not tested for hepatitis C virus (mainly due to poor reliability of serological assays in African patients) nor assessed for other confounders, such as alcohol consumption or other hepatotoxic medications, which may have contributed to the impaired immunological response or elevated transaminases in some patients. Finally, it was not possible to measure HIV-RNA: this may have been a confounder if more coinfected patients had non-suppressed HIV-RNA leading to blunted CD4 responses.
In summary, our study suggests that whilst standard first-line ART is well tolerated in most HIV/HBV-coinfected Ghanaians over 36 months of follow-up, HBV-coinfected patients have reduced CD4 cell responses, maintain high levels of HBV replication and are at significant risk of HBV lamivudine resistance. There is a pressing need to establish screening, monitoring and treatment programmes for HBV coinfection in Ghana and other regions of Africa where the prevalence of HBV coinfection is high. As tenofovir is now starting to replace stavudine and zidovudine as the main first-line nucleoside reverse transcriptase inhibitor in many African countries, including Ghana, further research is needed to establish the burden of liver disease in HBV-coinfected patients and assess the likely benefit of tenofovir in populations with a prolonged history of lamivudine exposure.
